In a pivotal trial, SPINRAZA achieved significant results in important milestones compared to untreated control group
Who: 121 children aged 7 months and younger with Type 1 (early-onset) SMA (80 children were treated with SPINRAZA versus 41 who were given a placebo)
Study time: 13 months
Primary outcomes:
Safety: The most common side effects were lower respiratory infection (55%; 44/80) and constipation (35%; 28/80). Serious adverse reactions of collapsed lung (atelectasis) were more frequent in the SPINRAZA-treated group (18%; 14/80) than in the control group (10%; 4/41).
“Whether she can or can't do
something, she's going to try.”